优化中国男性不育患者Y染色体微缺失筛查:一项关于发病率的大规模多中心研究
该回顾性多中心队列研究纳入2013年9月至2024年1月期间接受生育评估和AZF基因检测的6806例男性患者,通过ROC分析确定精子浓度预测AZF缺失的效能(AUC 0.75,95%CI 0.74-0.77),并识别出三个临床相关筛查阈值:ROC最优截断值0.45百万/ml、高灵敏度截断值8百万/ml和成本效益阈值1百万/ml。
要点
- 非梗阻性无精子症患者YCM发生率为12.71%,精子浓度0-1百万/ml者为13.35%,1-5百万/ml者为3.56%。
- 0.45百万/ml阈值灵敏度86.84%、特异度59.97%、PPV 13.48%、NPV 98.45%。
- 8百万/ml阈值灵敏度100.00%、NPV 100.00%,但特异度30.32%、PPV 9.34%。
核心结论
- 本研究为优化男性不育评估中的YCM筛查策略提供了综合证据,识别出0.45百万/ml、8百万/ml和1百万/ml三个临床相关筛查阈值。
研究设计与样本
- 回顾性多中心队列研究,纳入2013年9月至2024年1月期间接受生育评估和AZF基因检测的6806例男性患者。
主要发现
- YCM在非梗阻性无精子症患者中发生率为12.71%,在精子浓度0-1百万/ml患者中为13.35%,在1-5百万/ml患者中为3.56%。
- 精子浓度预测AZF缺失的AUC为0.75(95%CI 0.74-0.77)。
- 0.45百万/ml阈值灵敏度86.84%、特异度59.97%、PPV 13.48%、NPV 98.45%。
- 8百万/ml阈值灵敏度100.00%、NPV 100.00%,特异度30.32%、PPV 9.34%。
- 模型校准良好,Brier评分0.06,拟合优度检验P值0.726;成本效益分析显示1百万/ml阈值的增量成本效果比最低。
关键数值与推荐
- ROC最优截断值为0.45百万/ml,高灵敏度截断值为8百万/ml,成本效益阈值为1百万/ml。
临床怎么用
- 原文未据此给出推荐。
局限性
- 尽管是迄今最大队列研究,数据主要来自中国东部尤其是浙江地区,全国多中心研究可进一步验证。
- 成本效益分析使用基于GDP的总体支付意愿阈值,疾病特异性阈值可能更合适,且结果基于中国医疗体系,可能不直接适用于其他国家。
- 成本效益分析可能未完全捕捉非无精子症男性YCM检测的复杂下游影响,未来研究应考虑代际效应和ART潜在成本。
- 尽管严格排除了梗阻因素,回顾性设计可能引入选择偏差,未来前瞻性研究可解决。
- 部分患者禁欲时长精确信息因数据收集困难无法获取,未纳入本文,计划在未来前瞻性研究中探索其影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the optimal sperm concentration threshold for screening Y-chromosome microdeletions (YCMs) in male infertility patients? SUMMARY ANSWER: This study identified three clinically relevant screening thresholds: an receiver operating characteristic (ROC)-optimal cutoff at 0.45 million sperm/ml, a high-sensitivity cutoff at 8 million sperm/ml, and a cost-effective threshold at 1 million sperm/ml. WHAT IS KNOWN ALREADY: YCMs are the second most common genetic cause of male infertility, however, current screening thresholds remain controversial due to limited supporting evidence. STUDY DESIGN, SIZE, DURATION: This retrospective multi-centre cohort study included 6806 male patients who underwent fertility assessments and azoospermia factor (AZF) gene testing between September 2013 and January 2024. PARTICIPANTS/MATERIALS, SETTING, METHODS: ROC analysis was used to determine the AUC to show the effectiveness of sperm concentration for predicting AZF deletions. The sensitivity and specificity of different sperm concentration screening thresholds were measured. MAIN RESULTS AND THE ROLE OF CHANCE: The incidence of YCMs was found to be 12.71% in non-obstructive azoospermia patients, 13.35% in patients with sperm concentrations between 0 and 1 million/ml, and 3.56% in those between 1 and 5 million/ml. ROC analysis demonstrated that sperm concentration was a good predictor of AZF deletions (AUC: 0.75, 95% CI: 0.74-0.77). The optimal threshold of 0.45 million/ml yielded a sensitivity of 86.84%, specificity of 59.97%, positive predictive value (PPV) of 13.48%, and negative predictive value (NPV) of 98.45%. A threshold of 8 million/ml achieved maximum sensitivity of 100.00% and NPV of 100.00%, but with specificity of 30.32% and PPV of 9.34%. The model showed good calibration with a Brier score of 0.06 and a goodness-of-fit test P-value of 0.726. Cost-effectiveness analysis revealed that a threshold of 1 million/ml provided the lowest incremental cost-effectiveness ratio. LIMITATIONS, REASONS FOR CAUTION: Firstly, despite being the largest cohort study to date, our data primarily originated from eastern China, particularly the Zhejiang region. A nationwide multi-centre study could further validate our findings across different Chinese populations. Secondly, our cost-effectiveness analysis uses general gross domestics product-based willingness-to-pay thresholds, while disease-specific thresholds might be more appropriate and could be explored through nationwide surveys. Moreover, it is important to note that our cost-effectiveness findings are specifically based on the Chinese healthcare system and may not be directly applicable to other countries due to variations in healthcare systems, insurance coverage, and patient payment responsibilities across different regions globally. Another limitation of our cost-effectiveness analysis is that it may not fully capture the complex downstream implications of YCM detection in non-azoospermic men, where the primary impact relates to reproductive choices. Future studies should consider incorporating intergenerational effects and the potential costs of ART in subsequent generations when evaluating the true cost-effectiveness of YCM screening strategies. Thirdly, while we rigorously excluded cases with obstructive factors, the retrospective nature of our study might have introduced an inherent selection bias that could be addressed in future prospective studies. Fourthly, due to challenges in data collection, precise information on abstinence duration for some patients was unavailable and, therefore, not included in this article. We plan to further explore their potential impact on our conclusions in future prospective studies. WIDER IMPLICATIONS OF THE FINDINGS: This large-scale study provides comprehensive evidence for optimizing YCM screening strategies in male infertility evaluations. STUDY FUNDING/COMPETING INTEREST(S): This project was supported by the Medical and Health Technology Program of Zhejiang Province (2025KY085), the Zhejiang Health Information Association Research Program (2024XHSZ-Z05), the Scientific Research Fund of Zhejiang Provincial Education Department (Y202249537), and the National Natural Science Foundation of China (82471638). There are no known competing interests. TRIAL REGISTRATION NUMBER: N/A.
引用
- Chen WK, Liu ZB, Lin TT, et al. Optimizing Y-chromosome microdeletion screening in Chinese male infertility patients: a large-scale multi-centre study on incidence. Hum Reprod. 2025. PMID: 40121692. doi:10.1093/humrep/deaf043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。